Lipella Pharmaceuticals Shares Outstanding History (LIPO)
Lipella Pharmaceuticals reported 1.2M shares outstanding at the end of fiscal 2024.
View full Lipella Pharmaceuticals company overviewLipella Pharmaceuticals annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2024 | 2024-12-31 | 1.2M | 452,176 | +59.75% |
| 2023 | 2023-12-31 | 756,743 | 38,748.5 | +5.40% |
| 2022 | 2022-12-31 | 717,994.5 | 234,666.375 | +48.55% |
| 2021 | 2021-12-31 | 483,328.125 | — | — |
Lipella Pharmaceuticals quarterly shares outstanding
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q3 2025 | 2025-09-30 | 4.6M | 3.5M | +323.46% |
| Q2 2025 | 2025-06-30 | 4.5M | 3.5M | +369.90% |
| Q1 2025 | 2025-03-31 | 2.5M | 1.7M | +189.64% |
| Q4 2024 | 2024-12-31 | 1.2M | 452,176 | +59.75% |
| Q3 2024 | 2024-09-30 | 1.1M | 365,711.875 | +50.41% |
| Q2 2024 | 2024-06-30 | 950,704.5 | 232,711.375 | +32.41% |
| Q1 2024 | 2024-03-31 | 879,980.75 | 161,987.625 | +22.56% |
| Q4 2023 | 2023-12-31 | 756,743 | 38,748.5 | +5.40% |
| Q3 2023 | 2023-09-30 | 725,493.125 | — | — |
| Q2 2023 | 2023-06-30 | 717,993.125 | — | — |
| Q1 2023 | 2023-03-31 | 717,993.125 | — | — |
| Q4 2022 | 2022-12-31 | 717,994.5 | 234,666.375 | +48.55% |
| Q4 2021 | 2021-12-31 | 483,328.125 | — | — |
Lipella Pharmaceuticals shares outstanding trends
Between the periods ended 2021-12-31 and 2024-12-31, Lipella Pharmaceuticals's shares outstanding moved from 483,328.125 to 1.2M, a change of 725,590.875. The latest reported quarter, Q3 2025, shows 4.6M.
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when a stock-split conversion ratio is reported directly or evidenced by a later filing’s restated historical share balance. After repeated reverse splits, an old period can represent less than one current-basis share; this is a split-adjusted equivalent, not a literal historical certificate count. Values remain as reported when no reliable split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Lipella Pharmaceuticals source filings ↗